• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Combination therapy more effective than monotherapy for diabetic peripheral neuropathic pain

byNeel MistryandTeddy Guo
September 6, 2022
in Chronic Disease, Endocrinology, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. At week 16, average neuropathic pain score decreased for all three treatment groups.

2. Pain reduction was greater in the combination therapy group compared to monotherapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Peripheral neuropathy is a common microvascular complication associated with diabetes and is often a significant quality-of-life burden for patients. First-line medications for neuropathic pain include amitriptyline, duloxetine, pregabalin, and gabapentin. However, little is known about their comparative efficacies and the optimal combination for symptom relief. This randomized controlled trial aimed to assess the safety and efficacy of different first-line neuropathic medications for the treatment of diabetic peripheral neuropathic pain (DPNP). More specifically, this study assessed the relative efficacies of combinations comprising of amitriptyline-pregabalin, pregabalin-amitriptyline, duloxetine-pregabalin, and each monotherapy separately. The primary outcome was mean change in daily pain during week 16 of each pathway while key secondary outcomes included daily pain score at week 6 and quality of life. According to study results, average daily pain during the final week decreased in all three pathways and was similar between treatment groups. In addition, participants who initially received monotherapy but switched to combination therapy showed significantly improved pain scores compared to those who remained on monotherapy. However, this study was limited by self-reported pain, a subjective marker that differs from patient to another.

Click to read the study in The Lancet

Relevant Reading: Efficacy of Low-Dose Amitriptyline for Chronic Low Back Pain

In-depth [randomized-controlled trial]: In the OPTION-DM study, 252 patients were screened for eligibility across 13 centers in the UK between Nov 14, 2017, and Jul 29, 2019. Included were patients ≥ 18 years with known diabetes, distal symmetrical polyneuropathy, and neuropathic pain ≥ 3 months. Patients were randomly assigned to monotherapy with pregabalin, amitriptyline, or duloxetine, or one of 3 pathways: amitriptyline supplemented with pregabalin (A-P), pregabalin supplemented with amitriptyline (P-A), and duloxetine supplemented with pregabalin (D-P) for 16 weeks. At week 16, average pain score decreased from 6.6 (standard deviation [SD] 1.5) to 3.3 (SD 1.8) in all 3 pathways (intergroup difference: -0.1 D-P vs. A-P, -0.1 P-A vs. A-P, and 0.0 P-A vs. D-P) without any significant differences between combination treatment groups. Mean pain reduction was greater in the combination therapy group (1.0, SD 1.3) compared to monotherapy (0.2, SD 1.5). Majority of adverse events were mild in severity, including nausea, dizziness, and dry mouth. The P-A combination had significantly fewer discontinuations due to treatment-emergent adverse events compared to A-P and D-P (5% vs. 11% vs. 17%, respectively; p=0.031). Findings from this study suggest that all three treatment groups were comparable in efficacy although further research is needed.

RELATED REPORTS

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Amitriptylinediabetesdiabetes mellitusdiabetic peripheral neuropathic painDuloxetineendocrinologyneuropathic painneuropathyperipheral neuropathypregabalintype 2 diabetesType 2 Diabetes Mellitus
Previous Post

The CREDENCE trial: The effect of canagliflozin on renal function [Classics Series]

Next Post

Frailty as a predictor of mortality on admission to intermediate care

RelatedReports

Type 2 diabetes associated with reduction in disability-free life years
Chronic Disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

January 16, 2023
Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
Cardiology

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

December 26, 2022
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease

December 26, 2022
Next Post

Frailty as a predictor of mortality on admission to intermediate care

#VisualAbstract: Nirmatrelvir associated with improved COVID-19 outcomes in older adults

#VisualAbstract: Nirmatrelvir associated with improved COVID-19 outcomes in older adults

“No Evidence of Disease Activity” may be useful goal in multiple sclerosis

Excitatory noninvasive brain stimulation interventions improved negative symptoms in schizophrenia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Community-based adult vision screening program increases access to eye care
  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options